Blastic plasmacytoid dendritic cell neoplasm revealed by ecchymotic lesions on the face

Cutaneous CD4+CD56+ malignant tumor proliferation was previously called "CD4/CD56 hematodermic neoplasm". However, the most recent studies have shown that the disease develops from plasmacytoid dendritic cells and the tumor has been renamed "Blastic Plasmacytoid Dendritic Cell Neoplas...

Full description

Saved in:
Bibliographic Details
Published in:Annales de dermatologie et de vénéréologie 2014-01, Vol.141 (1), p.43-47
Main Authors: Ahogo, K-C, Wantz, M, Cliquennois, M, Gosset, P, Lebas, D, Modiano, P
Format: Article
Language:fre
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Asparaginase - administration & dosage
Biomarkers, Tumor
Biopsy
Bone Marrow Transplantation
CD4 Antigens - analysis
CD56 Antigen - analysis
Combined Modality Therapy
Dendritic Cells - pathology
Dexamethasone - administration & dosage
Ecchymosis - etiology
Facial Dermatoses - etiology
Hematologic Neoplasms - diagnosis
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - pathology
Hematologic Neoplasms - surgery
Humans
Immunophenotyping
Male
Methotrexate - administration & dosage
Proto-Oncogene Proteins - analysis
Transplantation, Autologous
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous CD4+CD56+ malignant tumor proliferation was previously called "CD4/CD56 hematodermic neoplasm". However, the most recent studies have shown that the disease develops from plasmacytoid dendritic cells and the tumor has been renamed "Blastic Plasmacytoid Dendritic Cell Neoplasm" (BPDCN). It is an aggressive disease with a poor prognosis and behaves like acute leukemia in the short to moderate term. A 65-year-old man with no particular history consulted for a left laterocervical lesion of ecchymotic aspect that had appeared one year earlier. Topical corticosteroid therapy had been unsuccessful. Examination of biopsies with lymphocyte typing enabled a diagnosis of BPDCN to be made. At the histopathological level, biopsy showed an infiltrate comprising medium to large cells. Immunohistochemical examination was remarkable for the absence of expression of markers of T- and B-cell lines. However, these tumor cells expressed CD4, CD56 and TCL1. Staging of the disease was normal. Treatment with chemotherapy was initiated in collaboration with a team of hematologists. Autologous bone marrow transplant was then performed. BPDCN is a rare malignant blood dyscrasia. It is distinguished by inaugural skin involvement, with systemic manifestations occurring much later. Histopathological examination of a skin biopsy with immunostaining establishes the diagnosis. In terms of phenotype, the tumor population is highly characteristic. The cells are negative for antigens of T- and B- cell lines. However, these cells express CD4, CD56 and TCL1, which are markers of plasmacytoid dendritic cells. The disease carries a poor prognosis and evolves in the short to middle term in the same way as acute leukemia. First-line treatment consists of the chemotherapy regimens used in aggressive lymphoma or acute leukemia. A bone marrow graft is sometimes performed at the time of initial relapse. Average survival is 12 months for chemotherapy alone and 30 months for transplant after first relapse. Early bone marrow transplantation has been shown to improve survival.
ISSN:0151-9638
DOI:10.1016/j.annder.2013.10.042